PMC:7558914 / 8728-10062
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
187 | 40-48 | Species | denotes | patients | Tax:9606 |
188 | 116-124 | Species | denotes | patients | Tax:9606 |
189 | 168-176 | Species | denotes | Patients | Tax:9606 |
190 | 1112-1120 | Species | denotes | patients | Tax:9606 |
191 | 1222-1229 | Species | denotes | patient | Tax:9606 |
192 | 217-235 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
193 | 239-258 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
194 | 278-296 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
195 | 302-314 | Chemical | denotes | azithromycin | MESH:D017963 |
196 | 318-337 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
197 | 362-380 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
198 | 382-394 | Chemical | denotes | azithromycin | MESH:D017963 |
199 | 400-419 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
200 | 421-439 | Chemical | denotes | Hydroxychloroquine | MESH:D006886 |
201 | 486-505 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
202 | 650-662 | Chemical | denotes | Azithromycin | MESH:D017963 |
203 | 772-790 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
204 | 805-817 | Chemical | denotes | azithromycin | MESH:D017963 |
205 | 839-857 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
206 | 913-932 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
207 | 967-979 | Chemical | denotes | azithromycin | MESH:D017963 |
208 | 999-1010 | Chemical | denotes | Chloroquine | MESH:D002738 |
209 | 1071-1089 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
210 | 1150-1169 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
211 | 1204-1214 | Chemical | denotes | remdesivir | MESH:C000606551 |
212 | 65-84 | Disease | denotes | respiratory illness | MESH:D012140 |
213 | 157-166 | Disease | denotes | pneumonia | MESH:D011014 |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T15 | 65-84 | Phenotype | denotes | respiratory illness | http://purl.obolibrary.org/obo/HP_0002086 |
T16 | 157-166 | Phenotype | denotes | pneumonia | http://purl.obolibrary.org/obo/HP_0002090 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T55 | 0-167 | Sentence | denotes | Antiviral treatment was recommended for patients with mild upper respiratory illness with clinical risk factors and patients with mild, moderate, and severe pneumonia. |
T56 | 168-420 | Sentence | denotes | Patients could be treated with monotherapy using hydroxychloroquine or lopinavir/ritonavir; dual therapy with hydroxychloroquine plus azithromycin or lopinavir/ritonavir; or triple therapy with hydroxychloroquine, azithromycin, and lopinavir/ritonavir. |
T57 | 421-649 | Sentence | denotes | Hydroxychloroquine could be used in four different regimens, and lopinavir/ritonavir could be used in two different regimens, with varied dosages and duration of treatment—either a short (5-day) regimen or long (10-day) regimen. |
T58 | 650-724 | Sentence | denotes | Azithromycin was recommended at the same dosage and duration of treatment. |
T59 | 725-818 | Sentence | denotes | Protocols included the combination of all four hydroxychloroquine regimens with azithromycin. |
T60 | 819-998 | Sentence | denotes | Regimens 1 and 3 of hydroxychloroquine were combined in dual therapy with the two regimens of lopinavir/ritonavir, which in turn were combined with azithromycin in triple therapy. |
T61 | 999-1108 | Sentence | denotes | Chloroquine 500 mg twice per day was recommended as an alternative when hydroxychloroquine was not available. |
T62 | 1109-1263 | Sentence | denotes | In patients with three antiviral agents, lopinavir/ritonavir could be replaced with once-daily remdesivir if the patient was enrolled in a clinical trial. |
T63 | 1264-1334 | Sentence | denotes | The dosage and durations of antiviral treatments are shown in Table 1. |